articleTop 1% cited
The prevalence of antiretroviral drug resistance in the United States
AIDS · 2004 · Vol. 18(10) · pp. 1393–1401
Douglas D. Richman✉(VA San Diego Healthcare System)Sally C. Morton(RAND Corporation)Terri Wrin(VIR Biotechnology (United States))Nicholas S. Hellmann(VIR Biotechnology (United States))Sandra Berry(RAND Corporation)Martin F. Shapiro(University of California, Los Angeles)Samuel A. Bozzette(RAND Corporation)
Abstract
The frequent selection for drug-resistant virus among viremic patients during the first 3 years of widespread use of potent antiretroviral combination therapy has significant implications for HIV treatment and transmission.
HIV/AIDS drug development and treatmentHIV Research and TreatmentHIV/AIDS Research and InterventionsMedicineViremiaViral loadDrug resistancePopulationHIV drug resistanceImmunologyEfavirenzInternal medicineOdds ratio
MeSH terms
AdolescentAdultAgedFemaleHumansMaleMiddle AgedUnited StatesHIV InfectionsPrevalenceAntiretroviral Therapy, Highly ActiveDrug Resistance, Viral
Funding
- Center for AIDS Research, University of Washington
Citations
412
FWCI
23.77
field-weighted impact
References
18
Percentile
100%
vs. same field & year
Citations per year
Cited by
Trends in cancer risk among people with AIDS in the United States 1980–2002
AIDS · 2006 · 767 citations
References
A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1
Antimicrobial Agents and Chemotherapy · 2000 · 649 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.